Details

Autor(en) / Beteiligte

• Chmiel, James F
• Konstan, Michael W
• Accurso, Frank J
• Lymp, James
• Mayer-Hamblett, Nicole
• VanDevanter, Donald R
• Rose, Lynn M
• Ramsey, Bonnie W

Titel

Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis

Ist Teil von

• Journal of cystic fibrosis, 2015-11, Vol.14 (6), p.720-726

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Background High-dose ibuprofen (HDI) is a clinically beneficial anti-inflammatory regimen that may be a useful reagent to study induced sputum inflammatory marker changes over short study periods appropriate for early-phase CF clinical trials. Methods We conducted a 28-day, open-label, randomized, controlled trial among 72 clinically stable CF subjects (FEV1 ≥ 40% predicted) randomized to HDI or routine care that assessed IL-6, IL-8, TNF-α, IL-1-β, free neutrophil elastase, and white cell counts with differentials change from baseline in induced sputum. Results IL-6 was the only biomarker with significant within-group change: 0.13 log10 pg/mL mean reduction among ibuprofen-treated subjects (p = 0.04); and no change in the control group. IL-6 change between groups was statistically significant (p = 0.024). No other inflammatory biomarker differences were observed between groups after 28 days. Conclusion Although we studied only one agent, HDI, these results suggest that one month may be inadequate to assess anti-inflammatory candidates using markers from induced sputum.